Other
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five
Moderna Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five decreased by 3.2% to $2.26B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.8%, from $2.42B to $2.26B. Over 5 years (FY 2020 to FY 2025), Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five shows an upward trend with a 29.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
First reportedQ1 2018
Last reportedQ1 2026May 1, 2026
Metric ID:
other_available_for_sale_securities_debt_maturities_afte_2b276aHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.21B | $6.45B | $6.89B | $9.42B | $10.49B | $9.11B | $8.69B | $7.69B | $6.35B | $5.46B | $4.77B | $3.7B | $2.36B | $2.34B | $2.51B | $2.42B | $2.38B | $2.14B | $2.33B | $2.26B |
| QoQ Change | — | +53.1% | +6.9% | +36.6% | +11.4% | -13.1% | -4.6% | -11.5% | -17.5% | -13.9% | -12.7% | -22.5% | -36.1% | -1.1% | +7.3% | -3.4% | -2.0% | -9.9% | +9.1% | -3.2% |
| YoY Change | — | — | — | — | +148.9% | +41.2% | +26.0% | -18.3% | -39.5% | -40.0% | -45.1% | -51.9% | -62.8% | -57.2% | -47.4% | -34.4% | +0.6% | -8.4% | -6.9% | -6.8% |
Range$2.14B – $10.49B
CAGR-12.3%
Avg YoY Growth-12.6%
Median YoY Growth-26.4%
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five at Other Companies
Frequently Asked Questions
- What is Moderna's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five?
- Moderna (MRNA) reported debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five of $2.26B in Q1 2026.
- How has Moderna's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five changed year-over-year?
- Moderna's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five decreased by 6.8% year-over-year, from $2.42B to $2.26B.
- What is the long-term trend for Moderna's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five?
- Over 5 years (2020 to 2025), Moderna's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five has grown at a 29.6% compound annual growth rate (CAGR), from $638M to $2.33B.